The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease (0030-10)
Nonalcoholic Fatty Liver Disease
Coronary Artery Disease
|Study Design:||Time Perspective: Prospective|
|Official Title:||The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease|
|Study Start Date:||July 2010|
|Estimated Study Completion Date:||March 2011|
|Estimated Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|
Background: The most common cause of death in patients with NAFLD(Nonalcoholic Fatty Liver Disease) is CAD(Coronary Artery Disease). NAFLD patients have 65% more mortality than general population. The aim of our study is to diagnose early coronary artery disease in NAFLD patient by measuring of PLA2.
Methods: 60 patients with chest pain and low to intermediate risk for coronary events will undergo Cardiac CT and blood test measurement of enzyme PLA2, markers of inflammation: CRP, MDA(Malondialdehide), Paraoxonase, FFA(Free Fatty Acids), TG(Triglycerids) will performed.
CAD is defined as a stenosis of more than 50% in at least one major coronary artery, unstable plaque defined as low attenuated plaque <30HU and fatty liver defined as difference in liver and spleen attenuation value -10HU by using CT.
Expected results : we expect that PLA2 will higher in patients with patients with combination of CAD, unstable plaque and NAFLD.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01139632
|Ziv medical center liver unit|
|Safed, Israel, Israel, 13100|
|Principal Investigator:||Nimer Assy, MD||ZIV MEDICAL CENTER, SAFED ISRAEL|